CLINICAL RESEARCH: HYPERTENSION
Association of Atrial Natriuretic Peptide and Type A Natriuretic Peptide Receptor Gene Polymorphisms With Left Ventricular Mass in Human Essential Hypertension
Speranza Rubattu, MD*, ,*,
Giada Bigatti, MD ,
Anna Evangelista, PhD*,
Chiara Lanzani, MD,
Rosita Stanzione, PhD*,
Laura Zagato, BBSC,
Paolo Manunta, MD,
Simona Marchitti, BS*,
Vanessa Venturelli, MD,
Giuseppe Bianchi, MD,
Massimo Volpe, MD*, and
Paola Stella, MD
* IRCCS Neuromed, Polo Molisano University of Rome La Sapienza, Pozzilli, Italy
U.O. Cardiologia, IInd School of Medicine, University of Rome La Sapienza, S. Andrea Hospital, Rome, Italy
Division of Nephrology, Dialysis and Hypertension, University Vita e Salute, San Raffaele Hospital, Milan, Italy
Manuscript received July 23, 2005;
revised manuscript received December 7, 2005,
accepted December 13, 2005.
* Reprint requests and correspondence: Dr. Speranza Rubattu, IRCCS Neuromed, Localit Camerelle, 86077 Pozzilli (Isernia), Italy (Email: rubattu.speranza{at}neuromed.it).
OBJECTIVES: The goal of our study was to investigate the relationships between atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and type A natriuretic peptide receptor (NPRA) gene polymorphisms and left ventricular structure in human essential hypertension.
BACKGROUND: Experimental evidence supports a key role for natriuretic peptides in the modulation of cardiac mass. This relationship has not yet been described in human disease.
METHODS: A total of 203 hypertensive patients were studied by mono-bidimensional echocardiography. Three markers of the ANP gene (–C664G, G1837A, and T2238C polymorphisms) and a microsatellite marker of both NPRA and BNP genes were characterized.
RESULTS: Patients carrying the ANP gene promoter allelic variant had increased left ventricular mass index (117.4 ± 1.7 g vs. 95.7 ± 1.7 g, p = 0.005), left ventricular posterior wall thickness (1.14 ± 0.07 cm vs. 0.96 ± 0.01 cm, p < 0.0001), left ventricular septal thickness (1.12 ± 0.10 cm vs. 1.04 ± 0.01 cm, p = 0.01), and relative wall thickening (47.5 ± 4.1% vs. 39.4 ± 5.3%, p = 0.001) as compared with the wild-type genotype. These associations were independent from anthropometric factors and major clinical features and were confirmed in a large subgroup of never-treated hypertensive patients (n = 148). Carrier status of the ANP gene promoter allelic variant was associated with significantly lower plasma proANP levels: 1,395 ± 104 fmol/ml versus 3,110 ± 141 fmol/ml in hypertensive patients carrying the wild-type genotype (p < 0.05). A significant association for NPRA gene variants with left ventricular mass index and left ventricular septal thickness was found. The analysis of BNP did not reveal any effect on cardiac phenotypes.
CONCLUSIONS: Our findings show that the ANP/NPRA system significantly contributes to ventricular remodeling in human essential hypertension.
|
Abbreviations and Acronyms
| | ANOVA = analysis of variance | | ANP = atrial natriuretic peptide | | BNP = brain natriuretic peptide | | BP = blood pressure | | LVH = left ventricular hypertrophy | | LVM = left ventricular mass | | NPRA = type A natriuretic peptide receptor | | RFLP = restriction fragment length polymorphism | | ST = septal thickness |
|
This article has been cited by other articles:
|
|
|
|
 
M. Hartmann, B. V. Skryabin, T. Muller, A. Gazinski, J. Schroter, B. Gassner, V. O. Nikolaev, M. Bunemann, and M. Kuhn
Alternative Splicing of the Guanylyl Cyclase-A Receptor Modulates Atrial Natriuretic Peptide Signaling
J. Biol. Chem.,
October 17, 2008;
283(42):
28313 - 28320.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Parat, N. McNicoll, B. Wilkes, A. Fournier, and A. De Lean
Role of Extracellular Domain Dimerization in Agonist-Induced Activation of Natriuretic Peptide Receptor A
Mol. Pharmacol.,
February 1, 2008;
73(2):
431 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. I. Lynch, E. Boerwinkle, B. R. Davis, C. E. Ford, J. H. Eckfeldt, C. Leiendecker-Foster, and D. K. Arnett
Pharmacogenetic Association of the NPPA T2238C Genetic Variant With Cardiovascular Disease Outcomes in Patients With Hypertension
JAMA,
January 23, 2008;
299(3):
296 - 307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Conen, R. J. Glynn, J. E. Buring, P. M Ridker, and R. Y.L. Zee
Natriuretic Peptide Precursor A Gene Polymorphisms and Risk of Blood Pressure Progression and Incident Hypertension
Hypertension,
December 1, 2007;
50(6):
1114 - 1119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Vassalle, M. G. Andreassi, C. Prontera, M. Fontana, L. Zyw, C. Passino, and M. Emdin
Influence of ScaI and Natriuretic Peptide (NP) Clearance Receptor Polymorphisms of the NP System on NP Concentration in Chronic Heart Failure
Clin. Chem.,
November 1, 2007;
53(11):
1886 - 1890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Burnett Jr and T. M. Olson
Natriuretic Peptides and Myocardial Structure: Insights From Population Genetics
Hypertension,
April 1, 2007;
49(4):
765 - 766.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Gardner, S. Chen, D. J. Glenn, and C. L. Grigsby
Molecular Biology of the Natriuretic Peptide System: Implications for Physiology and Hypertension
Hypertension,
March 1, 2007;
49(3):
419 - 426.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Polymorphisms in ANP and Its Receptor Are Associated with Increased Left Ventricular Mass
Journal Watch (General),
September 21, 2006;
2006(921):
4 - 4.
[Full Text]
|
|
|
|
|
|
|
B. London
Natriuretic Peptides and Cardiac Hypertrophy
J. Am. Coll. Cardiol.,
August 1, 2006;
48(3):
506 - 507.
[Full Text]
[PDF]
|
|
|
|
